mRNA differencial expression data between scrambled siRNA-treated mice and HN1L siRNA-treated mice tumor samples. mRNA differencial expression data between scrambled siRNA-treated mice and HN1L siRNA-treated mice tumor samples

(HN1L) is a targetable breast cancer stem cell (BCSC) gene that is altered in 25% of whole breast cancer and significantly correlated with shorter overall or relapse-free survival in triple negative breast cancer (TNBC) patients. HN1L silencing reduced the population of BCSCs, inhibited tumor initiation, re-sensitized chemo-resistant tumors to docetaxel, and hindered cancer progression in multiple TNBC cell line derived xenografts. We used microarray to compare mRNA expression profiles from PDX BCM2665 xenograft tumors with or without HN1L knockdown, to identify role of HN1L in regulating cancer stem cells. Overall design: mRNA arrays were performed on 10 snap-frozen tumor samples from scrambled siRNA-treated and HN1L siRNA-treated BCM2665 xenografts (5 samples from each treatment group). Differencial expression was performed to identifiy significantly differencially expressed mRNA and corresponding pathways.

(HN1L)是一种可靶向的乳腺癌干细胞（breast cancer stem cell, BCSC）相关基因，在25%的乳腺癌病例中发生异常改变，且与三阴性乳腺癌（triple negative breast cancer, TNBC）患者更短的总生存期或无复发生存期显著相关。
敲低HN1L可减少乳腺癌干细胞群体、抑制肿瘤起始能力、使化疗耐药肿瘤重新对多西他赛产生敏感性，并在多株三阴性乳腺癌细胞系来源的异种移植模型中阻碍癌症进展。
本研究采用微阵列技术，对比了PDX BCM2665异种移植肿瘤在敲低与未敲低HN1L状态下的mRNA表达谱，以阐明HN1L在调控癌症干细胞中的作用。
实验整体设计：对经乱序siRNA处理与HN1L靶向siRNA处理的BCM2665异种移植瘤的10份速冻肿瘤样本（每组各5份样本）开展mRNA芯片检测。
通过差异表达分析，鉴定得到显著差异表达的mRNA及其对应的调控通路。